These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 39164924)

  • 1. Pharmacotherapy for cervical cancer: current standard of care and new perspectives.
    Ketch PW; Zaharias RS; Leath CA
    Expert Opin Pharmacother; 2024 Aug; 25(12):1591-1603. PubMed ID: 39164924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in locally advanced cervical cancer: Integrating KEYNOTE-A18 into management strategies.
    How JA; Jazaeri AA
    Med; 2024 Jun; 5(6):487-489. PubMed ID: 38878765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of nimotuzumab in combination with immunotherapy for a young recurrent cervical cancer patient: a case report and literature review.
    Shi M; Zhang Y
    Anticancer Drugs; 2024 Aug; 35(7):644-652. PubMed ID: 38950136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI Study): a study protocol of a prospective, single-arm, phase II trial.
    Chen J; Han Y; Hu Y; Feng X; Meng X; Guo S; Sun C; Chen G; Li K
    BMJ Open; 2023 May; 13(5):e067767. PubMed ID: 37253491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of chemoradiotherapy plus immune checkpoint inhibitors for the treatment of locally advanced cervical cancer: a systematic review and meta-analysis.
    Zhao Z; Ruan J; Fang M; Liu J; Liao G
    Front Immunol; 2024; 15():1459693. PubMed ID: 39351236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial.
    Chen J; Li C; Cao Y; Zhu L; Zhang B; You J; Hou H; Wang J; Yuan Z
    BMC Cancer; 2022 Jul; 22(1):793. PubMed ID: 35854236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of current and emerging treatments for cervical cancer.
    Duenas-Gonzalez A; Gonzalez-Fierro A
    Expert Opin Drug Metab Toxicol; 2019 Aug; 15(8):671-682. PubMed ID: 31340683
    [No Abstract]   [Full Text] [Related]  

  • 8. Complete remission of advanced and recurrent cervical cancer with pembrolizumab treatment- 3 case reports.
    Tung HJ; Wang CC; Liu FY; Lai CH
    Taiwan J Obstet Gynecol; 2021 Sep; 60(5):938-941. PubMed ID: 34507680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update.
    Verhoeven Y; Quatannens D; Trinh XB; Wouters A; Smits ELJ; Lardon F; De Waele J; van Dam PA
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
    Shi Y; Chen J; Shi B; Liu A
    Gynecol Oncol; 2022 Feb; 164(2):379-385. PubMed ID: 34920886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer.
    Tangjitgamol S; Katanyoo K; Laopaiboon M; Lumbiganon P; Manusirivithaya S; Supawattanabodee B
    Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010401. PubMed ID: 25470408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
    Kokka F; Bryant A; Brockbank E; Powell M; Oram D
    Cochrane Database Syst Rev; 2015 Apr; (4):CD010260. PubMed ID: 25847525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab in recurrent advanced cervical squamous carcinoma.
    Martínez P; Del Campo JM
    Immunotherapy; 2017 May; 9(6):467-470. PubMed ID: 28399693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer.
    Duska LR; Scalici JM; Temkin SM; Schwarz JK; Crane EK; Moxley KM; Hamilton CA; Wethington SL; Petroni GR; Varhegyi NE; Clift SH; Bullock TNJ; Showalter TN
    Cancer; 2020 Nov; 126(22):4948-4956. PubMed ID: 32910478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in paclitaxel combinations for treating cervical cancer.
    Della Corte L; Barra F; Foreste V; Giampaolino P; Evangelisti G; Ferrero S; Bifulco G
    Expert Opin Pharmacother; 2020 Apr; 21(6):663-677. PubMed ID: 32037907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer.
    Krill LS; Tewari KS
    Expert Opin Pharmacother; 2015 Apr; 16(5):675-83. PubMed ID: 25643984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant Chemotherapy in Locally Advanced Cervical Cancer After Treatment with Concomitant Chemoradiotherapy--Room for Improvement?
    Jelavić TB; Miše BP; Strikic A; Ban M; Vrdoljak E
    Anticancer Res; 2015 Jul; 35(7):4161-5. PubMed ID: 26124372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
    Grau JF; Farinas-Madrid L; Oaknin A
    Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locally advanced cervical cancer - neoadjuvant chemotherapy followed by concurrent chemoradiation and targeted therapy as maintenance: A phase II study.
    Benson R; Pathy S; Kumar L; Mathur S; Dadhwal V; Mohanti BK
    J Cancer Res Ther; 2019; 15(6):1359-1364. PubMed ID: 31898673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature.
    D'Oria O; Bogani G; Cuccu I; D'Auge TG; Di Donato V; Caserta D; Giannini A
    Expert Opin Pharmacother; 2024; 25(1):55-65. PubMed ID: 38159033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.